Desde la primera línea, buscando el mejor abordaje del paciente con Cáncer gástrico metastásico

16 / 56

RAINBOW: Phase 3 Randomized Study in 2nd-line Gastric and GEJ Cancer, Ramucirumab with
Paclitaxel (CP12-0922/I4T-IE-JVBE)
Until
Progression
Patient Population
• Gastric or GEJ adenocarcinoma (metastatic or locally advanced and unresectable)
• 1st-line therapy with platinum/fluoropyrimidine doublet, with or without anthracycline
• Patient experienced progression during 1 st-line therapy or within 4 months after 1st-line therapy
• ECOG PS 0/1
• No CNS metastases
Stratify by:
• Time to progression on 1st-
line therapy
(< 6 vs ≥ 6 months)
• Geographic region
• Disease measurablility
(measurable vs.
nonmeasurable)
Ramucirumab 8 mg/kg every
2 weeks
+ Paclitaxel 80 mg/m2 weekly
Placebo every 2 weeks
+ Paclitaxel 80 mg/m2 weekly
N = 663
S
C
R
E
EN
R
A
N
D
O
M
I
Z
E
1:1
• Tumor assessment every 6 weeks
• Survival follow-up
• Safety follow-up